» Articles » PMID: 8555486

Activated Protein C Attenuates Endotoxin-induced Pulmonary Vascular Injury by Inhibiting Activated Leukocytes in Rats

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1996 Jan 15
PMID 8555486
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the effect of activated protein C (APC) on lipopolysaccharide (LPS)-induced pulmonary vascular injury in rats to investigate the possible usefulness of APC as a treatment for adult respiratory distress syndrome. Intravenously administered LPS (5 mg/kg) significantly increased pulmonary vascular permeability. APC prevented the LPS-induced increase in pulmonary vascular permeability observed at 6 hours. Heparin plus antithrombin III (ATIII) and active site-blocked factor Xa (DEGR-Xa), a selective inhibitor of thrombin generation, inhibited LPS-induced coagulopathy but did not prevent LPS-induced pulmonary vascular injury. LPS-induced pulmonary vascular injury was significantly attenuated in rats with nitrogen mustard-induced leukocytopenia and in rats treated with ONO-5046, a potent granulocyte elastase inhibitor. Administration of LPS also increased pulmonary accumulation of leukocytes, as evaluated by measurement of myeloperoxidase activity in the lungs. APC significantly reduced LPS-induced increases in pulmonary accumulation of leukocytes at 1 hour. Neither ATIII plus heparin nor DEGR-Xa inhibited leukocyte accumulation. Active site-blocked APC (DIP-APC) prevented neither the LPS-induced pulmonary accumulation of leukocytes nor the LPS-induced increase in pulmonary vascular permeability. These results suggest that the mechanism of APC inhibition of LPS-induced pulmonary vascular injury was independent of its anticoagulant activity and was related to its ability to inhibit accumulation of leukocytes. In addition, these findings suggest that the serine protease activity of APC may be essential to its inhibitory effect on LPS-induced pulmonary accumulation of leukocytes and subsequent pulmonary vascular injury.

Citing Articles

Immunity and Coagulation in COVID-19.

Avdonin P, Blinova M, Serkova A, Komleva L, Avdonin P Int J Mol Sci. 2024; 25(20).

PMID: 39457048 PMC: 11508857. DOI: 10.3390/ijms252011267.


Vascular leak in sepsis: physiological basis and potential therapeutic advances.

McMullan R, McAuley D, OKane C, Silversides J Crit Care. 2024; 28(1):97.

PMID: 38521954 PMC: 10961003. DOI: 10.1186/s13054-024-04875-6.


Targeting coagulation activation in severe COVID-19 pneumonia: lessons from bacterial pneumonia and sepsis.

Jose R, Williams A, Manuel A, Brown J, Chambers R Eur Respir Rev. 2020; 29(157).

PMID: 33004529 PMC: 7537941. DOI: 10.1183/16000617.0240-2020.


Suppressive Effects of GSS on Lipopolysaccharide-Induced Endothelial Cell Injury and ALI via TNF- and IL-6.

Yi L, Zhou Z, Zheng Y, Chang M, Huang X, Guo F Mediators Inflamm. 2020; 2019:4251394.

PMID: 32082076 PMC: 7012263. DOI: 10.1155/2019/4251394.


Endothelial cell-specific anticoagulation reduces inflammation in a mouse model of acute lung injury.

Lou J, Hu Y, Wu M, Che L, Wu Y, Zhao Y Acta Pharmacol Sin. 2018; 40(6):769-780.

PMID: 30446733 PMC: 6786365. DOI: 10.1038/s41401-018-0175-7.